Flavopiridol, an inhibitor of transcription: Implications, problems and solutions

Cell Cycle

Volumn 3, Issue 12, 2004, Pages 1537-1542

  Blagosklonny, Mikhail V ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cancer; CDK; Chemotherapy; Flavopiridol; p53; Transcription

Indexed keywords

5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; AMANITIN; ANTINEOPLASTIC AGENT; CYCLIN B; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR; DACTINOMYCIN; DEXAMETHASONE; DOCETAXEL; FAS LIGAND; FLAVOPIRIDOL; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; IRINOTECAN; NITRIC OXIDE SYNTHASE; PACLITAXEL; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; PROTEIN P53; SURVIVIN; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR E2F1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; CANCER; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPOTENSION; MITOSIS INHIBITION; NEUTROPENIA; NONHUMAN; REVIEW; SIDE EFFECT; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 17144391819     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.12.1278     Document Type: Review

References (99)

1. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992; 84:1736-40.
2. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK 4 in human breast carcinoma cells. Cancer Res 1996; 56:2973-8.
3. De Azevedo WFJ, M-D HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 1996; 93:2735-40.
4. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000; 92:378-87.
5. Newcomb EW. Flavopiridol: Pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs 2004; 15:411-9.
6. Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, Greene JF Jr, Koss W, Morgan CD, Stinson SF, Siford TJ, Alvord WG, Klabansky RL, Sausville EA. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood 1998; 91:2482-90.
7. Patel V, Senderowicz AM, Pinto D Jr, Igishi T, Raffeld M, Quintanilla-Martinez L, Ensley JF, Sausville EA, Gutkind JS. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998; 102:1674-81.
8. Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, Schwartz GK. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 2001; 7:4209-19.
9. Newcomb EW, Tamasdan C, Entzminger Y, Arena E, Schnee T, Kim M, Crisan D, Lukyanov Y, Miller DC, Zagzag D. Flavopiridol inhibits the growth of GL261 Gliomas in vivo: Implications for Malignant Glioma Therapy. Cell Cycle 2004; 3:230-4.
10. WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol Cancer Ther 2002; 1:253-66.
11. Grant S, Dent P. Conversion of drug-induced differentiation to apoptosis by pharmacologic cyclin-dependent kinase inhibitors. Cell Cycle 2002; 1:383-8.
12. Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 2002; 8:2976-84.
13. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003; 63:230-5.
14. Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz GK. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003; 2:549-55.
15. Nahta R, Trent S, Yang C, Schmidt EV. Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer. Cancer Res 2003; 63:3626-31.
16. Nguyen DM, Schrump WD, Tsai WS, Chen A, Stewart JH 4th, Steiner F, Schrump DS. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling pathway. J Thorac Cardiovasc Surg 2003; 125:1132-42.
17. Raju U, Nakata E, Mason KA, Ang KK, Milas L. Flavopitidol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res 2003; 63:3263-7.
18. Jung C, Motwani M, Kortmansky J, Sirotnak FM, She Y, Gonen M, Haimovitz-Friedman A, Schwartz GK. The Cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Clin Cancer Res 2003; 9:6052-61.
19. Camphausen K, Brady KJ, Burgan WE, Cerra MA, Russell JS, Bull EE, Tofilon PJ. Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Mol Cancer Ther 2004; 3:409-16.
20. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16:2986-99.
21. Rudek MA, Bauer KS Jr, Lush RM 3rd, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, Figg WD. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother 2003; 37:1369-74.
22. Aklilu M, Kindler HL, Donehower RC, Mani S, Vokes EE. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003; 14:1270-3.
23. Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A university of Chicago Phase II Consortium study. J Clin Oncol 2000; 18:371-5.
24. Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, Wainman N, Colevas AD, Eisenhauer EA. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004; 22:315-22.
25. Liu G, Gandara DR, Lara PN Jr, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res 2004; 10:924-8.
26. Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ Jr, Rollins BJ. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV nonsmall cell lung cancer. Clin Cancer Res 2001; 7:1590-9.
27. Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, Werner J, Perkins P, Stoltz M, Kelsen D. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001; 19:1985-92.
28. Smith SM, Liebowitz D, van Besien K, Fishkin P, Grinblatt D, Vokes EE. Flavopiridol monotherapy is inactive in mantle cell lymphoma. Blood 2003; 102:306B-306B, 4948(Part)4942.
29. Smith SM, Liebowitz D, van Besien K, Fishkin P, Grinblatt D, Vokes EE. Flavopiridol monotherapy is inactive in mantle cell lymphoma. Blood 2003; 102:306B-306B, 4948(Part)4942.
30. D'Amato G, Lima CR, Mahany JJ, Muro-Cacho C, Haura EB. Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with nonsmall-cell lung cancer: Case report and review of literature. Lung Cancer 2004; 44:381-90.
31. Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, Figg WD, Swain SM. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 2004; 10:5038-47.
32. Peng J, Zhu Y, Milton JT, Price DH. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev 1998; 12:755-62.
33. Chao SH, Price DH. Flavopiridoi inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001; 276:31793-9.
34. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001; 2:RESEARCH0041.
35. de Azevedo WFJ, Canduri F, da Silveira NJ. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 2002; 293:566-671.
36. Ni Z, Schwartz BE, Werner J, Suarez JR, Lis JT. Coordination of transcription, RNA processing, and surveillance by P-TEFb kinase on heat shock genes. Mol Cell 2004; 13:55-65.
37. De Falco G, Giordano A. CDK9: From basal transcription to cancer and AIDS. Cancer Biol Ther 2002; 1:342-7.
38. Garriga J, Grana X. Cellular control of gene expression by T-type cyclin/CDK9 complexes. Gene 2004; 337:15-23.
39. Price DH. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 2000; 20:2629-34.
40. Poele RHT, Okorokov AL, Joel SP. RNA synthesis block by 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells. Oncogene 1999; 18:5765-72.
41. Sobell HM. Actinomycin and DNA transcription. Proc Natl Acad Sci USA 1985; 82:5328-31.
42. Osathanondh R, Goldstein DP, Pastorfide GB. Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer 1975; 36:863-6.
43. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 2004; 64:3653-60.
44. Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997; 90:4307-12.
45. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pesrell R, Albanese C, Sausville EA, Senderowicz AM. Down regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1998; 59:4634-41.
46. Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderowicz AM. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999; 59:5433-7.
47. Kitada S, Zapata J, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96:393-7.
48. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002; 8:3527-38.
49. Ma Y, Cress WD, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther 2003; 2:73-81.
50. kip1 in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 2003; 17:2435-43.
51. Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Yamaguchi H, Huang M, Jove R, Wang HG, Bhalla K. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 2003; 63:93-9.
52. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004; 64:3517-24.
53. Grant S, Dent P. Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: What's in a name? Mol Cancer Ther 2004; 3:873-5.
54. Cartee L, Wang Z, Decker RH, Chellappan SP, Fusaro G, Hirsch KG, Sankala HM, Dent P, Grant S. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acecate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res 2001; 61:2583-91.
55. Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, Trepel JB, Schrump DS. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 2004; 10:1813-25.
56. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3:233-45.
57. Onega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, Barbero JL, Malumbres M, Barbacid M. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003; 35:25-31.
58. Aleem E, Berthet C, Kaldis P. Cdk2 as a master of S phase entry: Fact or fake? Cell Cycle 2004; 3:35-7.
59. Bible KC, Kaufmann SH. Flavopiridol: A cytotoxic flavone that induces cell death in non-cycling A549 human lung carcinoma cells. Cancer Res 1996; 56:4856-61.
60. Coppock DL, Pardee AB. Regulation of thymidine kinase activity in the cell cycle by a labile protein. J Cell Physiol 1985; 124:269-74.
61. Andera L, Wasylyk B. Transcription abnormalities potentiate apoptosis of normal human fibroblasts. Mol Medicine 1997; 3:852-63.
62. Koumenis C, Giaccia A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol 1997; 17:7306-16.
63. Shapiro GI, Koestner DA, Matranga CB, Rollins BJ. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in nonsmall cell lung cancer cell lines. Clin Cancer Res 1999; 5:2925-38.
64. Schwartz GK. CDK inhibitors: Cell cycle arrest versus apoptosis. Cell Cycle 2002; 1:122-3.
65. Newcomb EW, Tamasdan C, Entzminger Y, Alonso J, Friedlander D, Crisan D, Miller DC, Zagzag D. Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor. Cell Cycle 2003; 2:243-50.
66. Jaschke B, Milz S, Vogeser M, Michaelis C, Vorpahl M, Schomig A, Kastrati A, Wessely R. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury. FASEB J 2004; 18:1285-7.
67. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, Losiewicz MD, Pommier Y, Sausville EA, Senderowicz AM. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998; 91:458-65.
68. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002; 277:22320-9.
69. Zisman A, Ng CP, Pantuck AJ, Bonavida B, Belldegrun AS. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J Immunother 2001; 24:459-71.
70. Olsson A, Diaz T, Aguilac-Santelises M, Osterborg A, Celsing F, Jondal M, Osorio LM. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 2001; 15:1868-77.
71. Fulda S, Meyer E, Debatin KM. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res 2000; 60:3947-56.
72. Wong GHW, Goeddel DV. Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways. J Immunol 1994; 152:1751-5.
73. Kim DM, Koo SY, Jeon K, Kim MH, Lee J, Hong CY, Jeong S. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-α or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res 2003; 63:621-6.
74. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999; 5:1876-83.
75. Gao N, Dai Y, Rahmani M, Dent P, Grant S. Contribution of disruption of the NF-κB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol Pharmacol 2004; 66:956-63.
76. Dai Y, Rahmani M, Pei XY, Dent P, Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 2004; 104:509-18.
77. An WG, Chuman Y, Fojo T, Blagosklonny MV. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. Exp Cell Res 1998; 244:54-60.
78. Blagosklonny MV, Demidenko ZN, Fojo T. Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: P53 as a sensor of transcriptional integrity. Cell Cycle 2002; 1:67-74.
79. An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: Accumulation wt p53, p21 WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000; 14:1276-83.
80. Alonso M, Tamasdan C, Miller DC, Newcomb EW. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther 2003; 2:139-50.
81. Pepper C, Thomas A, Hoy T, Tighe J, Culligan D, Fegan C, Bentley P. Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol. Cell Cycle 2003; 2:53-8.
82. Blattner C, Sparks A, Lane D. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol Cell Biol 1999; 19:3704-13.
83. Lu X, Burgan WE, Cerra MA, Chuang EY, Tsai MH, Tofilon PJ, Camphausen K. Transcriptional signature of flavopiridol-induced tumor cell death. Mol Cancer Ther 2004; 3:861-72.
84. Rokhlin OW, Glover RA, Taghiyev AF, Guseva NV, Seftor RE, Shyshynova I, Gudkov AV, Cohen MB. Bisindolylmaleimide IX facilitates tumor necrosis factor receptor family-mediated cell death and acts as an inhibitor of transcription. J Biol Chem 2002; 277:33213-9.
85. Ljungman M, DP L. Opinion: Transcription - Guarding the genome by sensing DNA damage. Nat Rev Cancer 2004; 4:727-37.
86. Lu W Chen L, Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001; 20:3206-16.
87. WAF1/CIP1 expression. Cell Cycle 2002; 1:90-6.
88. Ferguson M, Luciani MG, Finlan L, Rankin EM, Ibbotson S, Fersht A, Hupp TR. The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death. Cell Cycle 2004; 3:80-9.
89. Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 2004; 0(12 Pt 2):4270s-5s.
90. Blagosklonny MV. Do cells need CDK2 and Bcr-Abl? Cell Death Differ 2004; 11:249-51.
91. Seibel NL, Dinndorf PA, Bauer M, Sondel PM, Hammond GD, Reaman GH. Phase I study of tumor necrosis factor-α and actinomycin D in pediatric patients with cancer: A children's cancer group study. J Immunother Emphasis Tumor Immunol 1994; 16:125-31.
92. Ding AH, Porteu F, Sanchez E, Nathan CF. Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 1990; 248:370-2.
93. Darzynkiewicz Z. Re: Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000; 92:1184-5.
94. WAF1/CIP1 and p53 and protects p21-sensitive cells from Paclitaxel. Cancer Biol Ther 2002; 1:420-5.
95. Pardee A. Role reversal for anti cancer agents. Cancer Biol Ther 2002; 1:426-7.
96. Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: Protection of normal cells and unshielding of cancer cells. Cell Cycle 2002; 1:375-82.
97. Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant S. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia 2004; In press.
98. Chiu YL, Cao H, Jacque JM, Stevenson M, Rana TM. Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J Virol 2004; 78:2517-29.
99. Schang LM. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim Biophys Acta 2004; 1697:197-209.